FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

ValueSets, Authority Hl7

17,520 resources

Source: Text:

By Version

By Realm

 

Start Prev Rows 6400 - 6600 Next

PackageVersionIdentityName/TitleStatusFMMWGDateRealmSource(s)
us.nlm.vsacR42.16.840.1.113883.3.600.1482Laboratory Tests for Hypertensionactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.1497Encounter to Screen for Blood Pressureactive2024-02uscms
us.nlm.vsacR42.16.840.1.113883.3.600.1508Lifestyle Recommendationactive2025-01ussct
us.nlm.vsacR42.16.840.1.113883.3.600.1509Weight Reduction Recommendedactive2022-02uscms
us.nlm.vsacR42.16.840.1.113883.3.600.1510Weight Reduction Recommendedactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.1511Dietary Recommendationsactive2025-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.1512Dietary Recommendationsactive2025-01uscms
us.nlm.vsacR42.16.840.1.113883.3.600.1514Dietary Recommendationsactive2017-05usicd
us.nlm.vsacR42.16.840.1.113883.3.600.1515Dietary Recommendationsactive2025-02usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.1516Exercise Classactive2017-05uscms
us.nlm.vsacR42.16.840.1.113883.3.600.1518Recommendation to Increase Physical Activityactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.1537Follow Up Within 4 Weeksactive2017-05ussct
us.nlm.vsacR42.16.840.1.113883.3.600.1538Encounter to Screen for Depressionactive2025-02uscpt
us.nlm.vsacR42.16.840.1.113883.3.600.1914Encounter to Screen for Depressionactive2020-03ussct
us.nlm.vsacR42.16.840.1.113883.3.600.1915Encounter to Screen for Depressionactive2023-02uscms
us.nlm.vsacR42.16.840.1.113883.3.600.1916Encounter to Screen for Depressionactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.1918Encounter to Screen for Blood Pressureactive2024-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.192Encounter to Screen for Blood Pressureactive2025-02uscpt
us.nlm.vsacR42.16.840.1.113883.3.600.1920Encounter to Screen for Blood Pressureactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.2387Overweight or Obeseactive2025-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.2388Underweightactive2022-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.2395Finding of Hypertensionactive2025-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.2462Laboratory Tests for Hypertensionactive2025-02usloinc
us.nlm.vsacR42.16.840.1.113883.3.600.2466Dental Tooth Extractionactive2022-02us
us.nlm.vsacR42.16.840.1.113883.3.600.259Diagnosis of Hypertensionactive2025-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.261Diagnosis of Hypertensionactive2021-02usicd
us.nlm.vsacR42.16.840.1.113883.3.600.263Diagnosis of Hypertensionactive2024-02usvsac
us.nlm.vsacR42.16.840.1.113883.3.600.467Follow Up for Adolescent Depressionactive2024-01ussct
us.nlm.vsacR42.16.840.1.113883.3.600.468Follow Up for Adult Depressionactive2024-01ussct
us.nlm.vsacR42.16.840.1.113883.3.600.469Adolescent Depression Medicationsactive2023-02usrx
us.nlm.vsacR42.16.840.1.113883.3.600.470Adult Depression Medicationsactive2024-02usrx
us.nlm.vsacR42.16.840.1.113883.3.600.537Referral for Adolescent Depressionactive2023-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.538Referral for Adult Depressionactive2023-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.791Patient Declinedactive2025-03ussct
us.nlm.vsacR42.16.840.1.113883.3.600.805Weight Reduction Recommendedactive2022-02ussct
us.nlm.vsacR42.16.840.1.113883.3.600.810Recommendation to Increase Physical Activityactive2017-05ussct
us.nlm.vsacR42.16.840.1.113883.3.600.823Referral or Counseling for Alcohol Consumptionactive2022-02ussct
us.nlm.vsacR42.16.840.1.113883.3.6366.117Absence of Cervixactive2024-08usicd
us.nlm.vsacR42.16.840.1.113883.3.666.5.1743General or Neuraxial Anesthesiaactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.666.5.1940Immunocompromised Conditionsactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.666.5.2262CABG Surgeriesactive2025-02ussct
us.nlm.vsacR42.16.840.1.113883.3.666.5.2328Immunocompromised Conditions I10active2022-02usicd
us.nlm.vsacR42.16.840.1.113883.3.666.5.2343Immunocompromised Conditionsactive2024-02ussct
us.nlm.vsacR42.16.840.1.113883.3.666.5.3011Acute Myocardial Infarctionactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.666.5.3024Acute Myocardial Infarctionactive2016-03ussct
us.nlm.vsacR42.16.840.1.113883.3.666.5.307Encounter Inpatientactive2020-03ussct
us.nlm.vsacR42.16.840.1.113883.3.666.5.335Bone Marrow Transplantactive2021-09ussct
us.nlm.vsacR42.16.840.1.113883.3.666.5.336Bone Marrow Transplantactive2024-01usvsac
us.nlm.vsacR42.16.840.1.113883.3.666.5.404Bone Marrow Transplantactive2024-02uscms
us.nlm.vsacR42.16.840.1.113883.3.666.5.623Acute Myocardial Infarctionactive2024-02usicd
us.nlm.vsacR42.16.840.1.113883.3.666.5.694CABG Surgeriesactive2024-02usvsac
us.nlm.vsacR42.16.840.1.113883.3.666.5.737PCIactive2018-08ussct
us.nlm.vsacR42.16.840.1.113883.3.666.5.747Endotracheal Intubationactive2017-05ussct
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.128Bipolar Disorderactive2024-02usvsac
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.246Personality Disorder Emotionally Labileactive2024-02usvsac
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.247Personality Disorder Emotionally Labileactive2022-02usicd
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.248Personality Disorder Emotionally Labileactive2022-02usicd
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.249Personality Disorder Emotionally Labileactive2023-03ussct
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.254Dysthymiaactive2022-02usvsac
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.256Dysthymiaactive2022-02usicd
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.257Dysthymiaactive2023-03ussct
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.262Deceasedactive2014-05ussct
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.263PHQ 9 and PHQ 9M Toolsactive2022-02usloinc
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.269Hepatitis Bactive2017-08usvsac
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.271Hepatitis Bactive2017-05usicd
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.272Hepatitis Bactive2023-02ussct
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.43Bipolar Disorderactive2022-02usicd
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.44Bipolar Disorderactive2025-02ussct
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.1.45Bipolar Disorderactive2022-02usicd
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.11.721Deceasedactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.67.1.101.11.723PHQ-9 Toolactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.6929.2.1000Estimated Glomerular Filtration Rateactive2024-02usloinc
us.nlm.vsacR42.16.840.1.113883.3.6929.2.1002Urine Albumin Creatinine Ratioactive2025-03usloinc
us.nlm.vsacR42.16.840.1.113883.3.6929.3.1000Estimated Glomerular Filtration Rateactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.6929.3.1007Urine Albumin Creatinine Ratioactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1000Strabismic Amblyopiaactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1001Strabismic Amblyopiaactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1002Refractive Amblyopiaactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1003Refractive Amblyopiaactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1004Routine Ophthalmological Examinationactive2019-09uscms
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1005Pediatric Best Corrected Visual Acuity Examactive2019-09usloinc
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1006LogMAR Visual Acuity Examactive2019-09usloinc
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1007Aphakiaactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1008Aphakiaactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1009Infantile and Juvenile Cataractactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1010Infantile and Juvenile Cataractactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1011Congenital Corneal or Anterior Segment Conditionsactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1012Congenital Corneal or Anterior Segment Conditionsactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1013Eyelid or Orbital Conditionsactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1014Eyelid or Orbital Conditionsactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1015Coloboma of Optic Discactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1016Coloboma of Optic Discactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1017Hemorrhage of Optic Nerve Sheathactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1018Hemorrhage of Optic Nerve Sheathactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1019Optic Nerve Hypoplasiaactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1020Optic Nerve Hypoplasiaactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1021Disorder of Visual Cortex Due to Underlying Conditionactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1022Disorder of Visual Cortex Due to Underlying Conditionactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1023Cortical Blindnessactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1024Cortical Blindnessactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1025Congenital Condition of Retinaactive2019-09usicd
us.nlm.vsacR42.16.840.1.113883.3.8420.2.1026Congenital Condition of Retinaactive2019-09ussct
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1000Strabismic Amblyopiaactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1001Refractive Amblyopiaactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1002Routine Ophthalmological Examinationactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1003Pediatric Best Corrected Visual Acuity Examactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1004LogMAR Visual Acuity Examactive2022-03usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1005Aphakiaactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1006Infantile and Juvenile Cataractactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1007Congenital Corneal or Anterior Segment Conditionsactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1008Eyelid or Orbital Conditionsactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1009Coloboma of Optic Discactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1010Hemorrhage of Optic Nerve Sheathactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1011Optic Nerve Hypoplasiaactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1012Disorder of Visual Cortex Due to Underlying Conditionactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1013Cortical Blindnessactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.8420.3.1014Congenital Condition of Retinaactive2019-09usvsac
us.nlm.vsacR42.16.840.1.113883.3.88.12.3221.6.2Allergy and Intolerance Typeactive2024-06ussct
us.nlm.vsacR42.16.840.1.113883.3.88.12.3221.7.2Problem Type (SNOMEDCT)active2025-05ussct
us.nlm.vsacR42.16.840.1.113883.3.88.12.3221.8.7SPL Drug Route of Administration Terminologyactive2024-07usncit
us.nlm.vsacR42.16.840.1.113883.3.88.12.80.62Vital Sign Result Typeactive2024-03usloinc
us.nlm.vsacR42.16.840.1.114222.4.11.3180NHSNInsertionSiteCodeactive2020-06ussct
us.nlm.vsacR42.16.840.1.114222.4.11.3181NHSNRoleOfPerformerCodeactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.3182NHSNReasonForInsertionCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.3183NHSNSkinPreparationCodeactive2020-08usrx
us.nlm.vsacR42.16.840.1.114222.4.11.3184NHSNSterileBarrierCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.3185NHSNCatheterTypeCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.3194NHSNSignificantPathogenCodeactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.3195NHSNCriterionOfDiagnosisCodeactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.3196NHSNInfectionConditionCodeactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.3234NHSNPopulationCategoryCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.3247NHSNTimingCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.3248NHSNEligibilityCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.3249NHSNSpecimenTypeCodeactive2025-02ussct
us.nlm.vsacR42.16.840.1.114222.4.11.3283NHSNOrganismASTCodeactive2020-06ussct
us.nlm.vsacR42.16.840.1.114222.4.11.3360NHSNAntimicrobialAgentAURPCodeactive2025-03usrx
us.nlm.vsacR42.16.840.1.114222.4.11.3361NHSNRouteOfAdministrationAURPCodeactive2020-07ussct
us.nlm.vsacR42.16.840.1.114222.4.11.3595NHSNPopulationSummaryReportTypeCodeactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.6007NHSNVascularAccessTypeCodeactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.6008NHSNSuspectedSourceTypeCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.6042NHSNVascularAccessSiteCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.6051NHSNClosureTechniqueCodeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.6074NHSNStaphAureusTestResultsactive2020-07ussct
us.nlm.vsacR42.16.840.1.114222.4.11.7160NHSNStaphAureusSpecificTestactive2020-07usloinc
us.nlm.vsacR42.16.840.1.114222.4.11.7214NHSNSameDayOutcomeMeasureactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.7215NHSNInfectionFirstReportedSourceactive2022-03usvsac
us.nlm.vsacR42.16.840.1.114222.4.11.7232NHSNRaceCategoryactive2020-06usoid
us.nlm.vsacR42.16.840.1.114222.4.11.7233NHSNPreviousPatientLocationactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7237NHSNBloodCollectionLocationactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7238NHSNPreviousFacilityactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7239NHSNContraindicationTypeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7240NHSNCarbaTestMethodactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7241NHSNCarbaDetectTypeactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7242NHSNCdiffTestMethodactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7338NHSNStartOrContinuationactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.7353NHSNSummaryBloodProductUsageactive2020-08uscdc
us.nlm.vsacR42.16.840.1.114222.4.11.836Raceactive2012-10usoid
us.nlm.vsacR42.16.840.1.114222.4.11.837Ethnicityactive2012-10usoid
us.nlm.vsacR42.16.840.1.114222.4.11.877Detailed Ethnicityactive2024-06usoid
us.nlm.vsacR42.16.840.113883.3.67.1.101.3.2444Major Depression Including Remissionactive2021-02usvsac
ca.ab.fhir.psabR4febd1976-2524-44ea-b31c-633d1329d76ev3.ConfidentialityClassification-AB-PSdraftcatho
hl7.terminologyR5v3-RoleCodev3 Code System RoleCodeactive0vocab2018-08uvtho
hl7.terminologyR5v3-ActReasonv3 Code System ActReasonactive1vocab2018-08uvtho
hl7.terminologyR5v3-ActSitev3 Value Set ActSiteactive2018-08uvtho
hl7.eu.fhir.pcspR4morphologicAbnormality-eu-vsMorphologically abnormal structuredraft2025-07eusct
us.nlm.vsacR42.16.840.1.113762.1.4.1222.140Ferritinactive2024-07usloinc
us.nlm.vsacR42.16.840.1.113883.3.464.1003.113.12.1005Rheumatoid Arthritisactive2024-01usvsac
us.nlm.vsacR42.16.840.1.113883.3.464.1003.113.11.1080Rheumatoid Arthritisactive2021-02usicd
us.nlm.vsacR42.16.840.1.113883.3.464.1003.113.11.1081Rheumatoid Arthritisactive2022-02ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1222.1428Myalgiaactive2024-06ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1222.1439Vomitingactive2024-07ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1222.1525Cognitive disorder Diagnosis ICD10active2024-06usicd
hl7.terminologyR5v3-ChronicCareFacilityChronicCareFacilityactive2014-03uvtho
hl7.fhir.us.ccdaR42.16.840.1.113883.11.20.4.1DischargeSummaryDocumentTypeCodetrial-usecgp2025-07usloinc
hl7.fhir.us.ccdaR42.16.840.1.113883.1.11.20.22HPDocumentTypetrial-usecgp2025-07usloinc
hl7.fhir.us.ccdaR42.16.840.1.113762.1.4.1099.10Care Plan Document Typetrial-usecgp2025-07usloinc
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1139S4G Hyperlipidemiaactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1291S4G Cardiomyopathyactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1292S4G Tricuspid valve disorderactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1293S4G Pompe diseaseactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1294S4G Malignant hyperthermiaactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1295S4G Malignancyactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1297S4G Intestinal polypactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1298S4G Hamartomaactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1299S4G Diabetes mellitusactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1300S4G Muscular dystrophy and weaknessactive2022-08ussct
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1325S4G Hamartoma and S4G Intestinal Polypactive2022-08usvsac
us.nlm.vsacR42.16.840.1.113762.1.4.1196.1326S4G Malignancy and S4G Intestinal Polypactive2022-08usvsac
hl7.terminologyR5v3-GeneralAcuteCareHospitalGeneralAcuteCareHospitalactive2014-03uvtho
hl7.terminologyR5v3-RehabilitationHospitalRehabilitationHospitalactive2014-03uvtho
hl7.terminologyR5v3-FontStyleFontStyleactive2014-03uvtho
hl7.terminologyR5v3-TableRuleStyleTableRuleStyleactive2014-03uvtho
hl7.terminologyR5v3-StyleTypeStyleTypeactive2014-03uvtho
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.12.8.2--20200901000000GCS_MotorCodelijstactivenltho oid
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.12.8.7--20200901000000GCS_MotorCodelijstKleuteractivenltho oid
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.12.8.8--20200901000000GCS_MotorCodelijstBabyactivenltho oid
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.12.8.4--20200901000000GCS_VerbalCodelijstKleuteractivenltho oid
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.12.8.3--20200901000000GCS_VerbalCodelijstactivenltho oid
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.12.8.5--20200901000000GCS_VerbalCodelijstBabyactivenltho oid
nictiz.fhir.nl.r4.zib2020R42.16.840.1.113883.2.4.3.11.60.40.2.5.1.3--20200901000000ProbleemNaamCodelijstactivenlfhir sct oid icpc